Cumulus Neuroscience Appoints Ricardo Sáinz Fuertes, MD as New Board Chair
BELFAST, Northern Ireland, Jan. 8, 2026 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on...
Neuroscience
Purina Spotlights Next Generation of Pet Care Innovation with 2026 Pet Care Innovation Prize Winners
Purina awards five startups advancing pet health, wellness and veterinary care with mentorship, $25,000 in funding and the chance to...
ORYZON to Participate in Upcoming Events in January
MADRID and CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical...
Headlamp Health Launches Lumos AI to De-Risk Neuroscience Drug Development
Agentic AI platform brings longitudinal real-world insight to improve trial design and decision-making; Zak Williams and Dr. Charles B. Nemeroff...
Headlamp Health Launches Lumos AI to De-Risk Neuroscience Drug Development
Agentic AI platform brings longitudinal real-world insight to improve trial design and decision-making; Zak Williams and Dr. Charles B. Nemeroff...
Headlamp Health Launches Lumos AI to De-Risk Neuroscience Drug Development
Agentic AI platform brings longitudinal real-world insight to improve trial design and decision-making; Zak Williams and Dr. Charles B. Nemeroff...
BioSpace Names 15 Top Startups to Watch in 2026
DES MOINES, Iowa, Jan. 7, 2026 /PRNewswire/ -- BioSpace, the leading life sciences news and careers site, has announced its...
Cumulus Neuroscience Publishes Data Validating a Scalable Measurement of Neuroplasticity Using Low-Burden Dry Sensor EEG
Data published in Scientific Reports confirms a low-burden visual evoked potential (VEP) assessment can be employed across multiple clinical trial sites as an...
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company...
SynuSight Biotech, ABLi Therapeutics and XingImaging Announce Strategic Collaboration to Implement Alpha-Synuclein PET Imaging into Clinical Trials Evaluating Risvodetinib as a Disease-modifying Therapy for Parkinson’s Disease
SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to...
MasterClass Launches a Class on Dopamine to Help Members Balance Pleasure and Pain in an Overloaded World
Stanford addiction psychiatrist and bestselling author teaches members how to reset their brain's reward system and feel in control in...
10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference
PLEASANTON, Calif., Dec. 29, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today...
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody’s Ratings Agency Revises Outlook to Positive
The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline.Moody's affirmed Teva's...
Historic $15 Million Gift Fuels Breakthrough Cancer Care at Hartford HealthCare St. Vincent’s Medical Center
The Estate of Neil Mellen Helps Build Destination for Advanced Cancer Care in ConnecticutBRIDGEPORT, Conn., Dec. 23, 2025 /PRNewswire/ -- Hartford...
Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6
Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical...
NUCALM CELEBRATES RECORD-BREAKING DECEMBER WITH OVER 2 BILLION MINUTES USED AND LARGEST LIVE EVENT ACTIVATION EVER
Tony Robbins' "Date with Destiny" Event Drives Unprecedented Engagement with NuCalm TechnologyPALM BEACH, Fla., Dec. 22, 2025 /PRNewswire/ -- NuCalm®,...
Sinaptica Therapeutics Completes Scientific Advisory Board, Bringing Together Leading Voices Across Patients, Science, Medicine, and Commercial Strategy
Sinaptica Therapeutics Scientific Advisory Board Sinaptica Therapeutics Completes Scientific Advisory Board, Bringing Together Leading Voices Across Patients, Science, Medicine, and...
Peer-Reviewed Studies Validate Linus Health AI as an Early Digital Biomarker for Alzheimer’s Pathology, Helping People Take Action Earlier to Slow Disease Impact
Findings show Linus Health's AI can indicate Alzheimer's pathology before noticeable symptoms—enabling earlier action to help protect independence and preserve...
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term...